Difference between revisions of "Combining-Ziprasidone-Topiramate"

From Psychiatrienet
Jump to: navigation, search
(Created page with '{{Drugcombi | base = ziprasidone | add = topiramate | info = * Ziprasidone is metabolized by CYP3A4 and CYP1A2 (minor). * Dose adaptation will be recommended for this combinatio...')
 
 
Line 3: Line 3:
 
| add = topiramate
 
| add = topiramate
 
| info =  
 
| info =  
* Ziprasidone is metabolized by CYP3A4 and CYP1A2 (minor).
 
 
* Dose adaptation will be recommended for this combination.
 
* Dose adaptation will be recommended for this combination.
 
* This combination of drugs may have possible synergistic effects. However, this combination will also have additive side effects.  
 
* This combination of drugs may have possible synergistic effects. However, this combination will also have additive side effects.  
 
 
| start =  
 
| start =  
 
* Start topiramate according general dosing advice.
 
* Start topiramate according general dosing advice.

Latest revision as of 15:13, 15 June 2010

Ziprasidone
Type Antipsychotic
Group Atypical AP
Other use Moodstabilizer
links
Medscape Ziprasidone
PubChem 60854
PubMed Ziprasidone
Wikipedia Ziprasidone
Topiramate
Type moodstabilizer
Group anticonvulsant
links
ATC-code N03AX11
PubChem 5284627
PubMed Topiramate
Drugs.com topiramate
Kompas (Dutch) Topiramate
Wikipedia Topiramate

Adding topiramate to ziprasidone.

Infobord.png General information
  
Ziprasidone
  • Ziprasidone is metabolized by CYP1A2 (minor) and CYP3A4.
  
Topiramate
  • Topiramate induces CYP3A4 and is an inhibitor of CYP2C19.
  
Ziprasidone
  
Topiramate
  • Dose adaptation will be recommended for this combination.
  • This combination of drugs may have possible synergistic effects. However, this combination will also have additive side effects.
Eenrichtingbord.png Start topiramate
  
Topiramate
  • Start topiramate according general dosing advice.
Nietinrijdenbord.png Stop topiramate
  
Topiramate
Letopbord.png Cave
  • Caution is advised when topiramate is prescribed with other drugs that predispose patients to heat-related disorders, including carbonic anhydrase inhibitors and drugs with anticholinergic activity. [2]


The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.